Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGXSWX:AFX 76 3-Year FCF Growth Rate is 8.60% as of Dec. 2025, which is 682% above its 10-year median of 1.10. GuruFocus rates XSWX:AFX with a GF Score™ of 76/100 and a GF Value™ of CHF70.36. The stock has 3 warning signs investors should review. Among 587 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 58.94% on this metric.
During the past 12 months, Carl Zeiss Meditec AG's average Free Cash Flow per Share Growth Rate was 15.80% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Carl Zeiss Meditec AG was 51.30% per year. The lowest was -31.40% per year. And the median was 1.10% per year.
Carl Zeiss Meditec AG (XSWX:AFX) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Carl Zeiss Meditec AG 3-Year FCF Growth Rate Related Terms
XSWX:AFX vs ISRG, BDX, RMD: 3-Year FCF Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's 3-Year FCF Growth Rate falls into.
Carl Zeiss Meditec AG 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Carl Zeiss Meditec AG (XSWX:AFX) has a 3-Year FCF Growth Rate of 8.60% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Carl Zeiss Meditec AG and its competitors. This is 682% above median its historical median of 1.10. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #346 out of 587 companies in the Medical Devices & Instruments industry, placing it in the top 58.9%.
Is Carl Zeiss Meditec AG's 3-Year FCF Growth Rate too high?
Carl Zeiss Meditec AG's current 3-Year FCF Growth Rate of 8.60% is 682% above median its 10-year median of 1.10. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Carl Zeiss Meditec AG's value of 8.60% is 52.2% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #346 out of 587 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's 3-Year FCF Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #346 out of 587 companies for 3-Year FCF Growth Rate. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. Carl Zeiss Meditec AG's value of 8.60% is 52.2% below this benchmark. While the company's 10-year median is 1.10 vs. the industry median of 18.00, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 587 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current 3-Year FCF Growth Rate of 8.60% is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current 3-Year FCF Growth Rate is 8.60%, which is 682% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XSWX:AFX) has a current 3-Year FCF Growth Rate of 8.60%. The stock's GF Value™ is CHF70.36, compared to a current price of CHF30.06 — trading 57.3% below its estimated fair value. The current 3-Year FCF Growth Rate is 8.60%, which is 682% above median its 10-year median of 1.10 and 52.2% below the Medical Devices & Instruments industry median of 18.00. Carl Zeiss Meditec AG's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current 3-Year FCF Growth Rate is 8.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF30.06 is trading 57.3% below its estimated GF Value™ of CHF70.36.
Key valuation signals for XSWX:AFX:
3-Year FCF Growth Rate: 8.60% (682% above median its 10-year median of 1.10)
GF Value™: CHF70.36 vs. price of CHF30.06 (57.3% below fair value)
Industry Position: 52.2% below the Medical Devices & Instruments median (#346 of 587)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
76GF Score
Get the complete analysis for XSWX:AFX
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
